The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

Many prefer to avoid toxins in the cleaning supplies used in their homes everyday, but there are some hidden chemicals you ...

An inhaler is a handheld device that delivers a puff or spray of these medicines straight into your lungs through a mouthpiece. Inhalers work faster than pills, which have to travel through your ...

NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

The most recent study, published in November 2024, examined data from more than 100,000 children aged 3–17 with asthma or hay fever who either took montelukast or used only inhaled corticosteroids.

Chiesi UK & Ireland has published new research revealing significant gaps in the understanding and practice of inhaler use among UK asthma patients. The study published in the BMJ Open Respiratory ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...